Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04864925 · ClinicalTrials.gov registry record · Phase 3
Measurement of Viral Load Reduction in the Oral Cavity After a Regimental Use of OC Toothpaste Products
A Phase 3 study, sponsored by Colgate Palmolive.
- Completed
- Registry status
- Phase 3
- Development phase
- 46
- Enrollment target
NCT04864925: Completed Phase 3 study, sponsored by Colgate Palmolive.
NCT04864925 is a Phase 3 study that has completed, run by Colgate Palmolive. The registered enrollment target is 46 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04864925, a Phase 3 study, has completed, sponsored by Colgate Palmolive.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 46 participants
- Enrollment target
Study Summary
SARS COVID 2 has caused a pandemic of proportions unparalleled in the past 100 years. The virus has an uncanny ability for transmission and as such has been difficult to control. The spread of the virus has affected everything from education, business, politics and survival. While the investigators have learned a great deal in the last 9 months they still face an uncertain day to day existence. Health care workers are particularly vulnerable to transmission of this virus because of their close contact with patients. Moreover, dentists are particularly vulnerable because the virus is spread via aerosols which are generated quite easily in the dental office putting dentists and their associates at risk. The oral cavity appears to be a likely domain for viral carriage particularly since both taste and smell are hallmark effects of the virus. With these issues at hand it will be of great advantage to have a simple routine oral hygiene method in the effort to reduce the oral viral load. There is some reason to expect that oral hygiene procedures with known anti-microbial effects could have some use in our efforts to reduce or control the oral viral load. With this issue in mind investigators feel that stannous fluoride could modify the virus in such a manner as to effectively reduce the oral viral load.
Primary Outcome
Primary outcome based on reductions of viral titers in the oral cavity as determined by qRT-PCR
Interventions
- DRUG Colgate Total Clean Mint
- DRUG Tom's Botanically Bright Peppermint
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2020-12-28 |
| Est. Completion | 2021-08-25 |
| Phase | Phase 3 |
What the finished NCT04864925 record still lists
NCT04864925 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 46 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 2 interventions - of which Colgate Total Clean Mint is the first listed.
NCT04864925 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04864925 about?
NCT04864925 is a clinical study titled "Measurement of Viral Load Reduction in the Oral Cavity After a Regimental Use of OC Toothpaste Products". SARS COVID 2 has caused a pandemic of proportions unparalleled in the past 100 years. The virus has an uncanny ability for transmission and as such has been difficult to control. The spread of the virus has affected everything from education, business, politics and survival. While the investigators ...
What is the current status of trial NCT04864925?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 46 participants. The study started on 2020-12-28. Estimated completion is 2021-08-25.
What interventions are being tested in trial NCT04864925?
The interventions under investigation include: Colgate Total Clean Mint (DRUG), Tom's Botanically Bright Peppermint (DRUG).
Who is sponsoring clinical trial NCT04864925?
This trial is sponsored by Colgate Palmolive, which has 51 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04864925's enrollment target sits among peer trials
46 1868th of 2000 higher than 131 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01890590 · 46 participants · NA
A Phase II Study of Cyberknife Radiosurgery for Renal Cell Carcinoma
- NCT03191149 · 46 participants · Phase 2
Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change
- NCT03510208 · 46 participants · Phase 1
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
- NCT04048278 · 46 participants · Early Phase 1
Lidocaine Infusion in Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI